NYSE · LLY
Eli Lilly and Company
$1,426.97+$53.27 (+3.88%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.57% below the high.
Loading market information…
OTC · RXEI · USD
Stock price
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RxElite, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
RxElite, Inc. is a pharmaceutical company that specializes in the development, production, and commercialization of generic prescription drugs, particularly within specialty markets. Its diverse product portfolio encompasses Sterile Liquid Dose offerings, such as generic ophthalmic solutions (available in both unit-dose and multi-dose formats), sterile unit-dose respiratory inhalation products, and various injectable medications. Beyond its finished drug products, the company, operating through its subsidiaries, also serves as a manufacturer of active pharmaceutical ingredients (APIs) for other pharmaceutical entities across the United States, Europe, and Asia. RxElite's extensive customer base includes institutional clients like hospitals and hospital group purchasing organizations, national and regional wholesale distributors, major direct retail pharmacy chains, home healthcare providers, and various outpatient surgery centers and ambulatory care clinics. The company maintains strategic alliances with industry partners such as Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. Headquartered in Meridian, Idaho, RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,426.97+$53.27 (+3.88%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.57% below the high.
$276.74+$1.54 (+0.56%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 1.85% below the high.
CA$3.50-CA$0.18 (-4.89%)
Tilray Brands, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.77% below the high.
CA$0.92-CA$0.02 (-2.13%)
Canopy Growth Corporation’s quoted price sits in the lower half of its reported 52-week range, 71.95% below the high.
$0.00$0.00 (0.0%)
PharmaCom BioVet, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
MedGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Wellstar International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Interpharm Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.76% below the high.
